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Introduction
Interstitial Lung Disease (ILD) is a severe complication
of systemic sclerosis, more common among patients
with diffuse scleroderma. Cyclophosphamide (CYC) is
the treatment normally used in those patients, with irre-
gular response. We have successfully treated 3 patients
refractory to CYC with Rituximab (RTX).
Patients and methods
-Patient 1: A 43 years-old woman developed progressive
cough and dyspnea, with radiological changes of intersti-
tial lung disease. She began treatment with oral gluco-
corticoids and monthly boluses of CYC (1g i.v).
-Patient 2: A 53 years-old woman with a diagnosis of dif-
fuse scleroderma three years earlier, started with dyspnea
during low strain at the beginning. ILD was diagnosed
with characteristic ground glass pattern on thoracic CT.
She was given 6 boluses of CYC and oral glucocorticoids
-Patient 3: A 48 years-old women, with skin lesions
suggestive of dermatomyositis (DM). In 2007 she was
diagnosed of amyopathic DM with scleroderma overlap.
Three 3 months after the diagnosis, she began with
cough and dry expectoration, together with dyspnea.
ILD was diagnosed with characteristic ground glass
pattern on thoracic CT. She was initially treated
monthly with CYC for 7 months. All patients, we started
a treatment with RTX (2x1g) plus CYC.
Results
Respiratory function tests showed improvements (See
table 1).
Conclusions
Overexpression of B lymphocytes in Scleroderma patho-
genesis, and the bad evolution of ILD in those patients
aimed us to try RTX (anti CD-20) after CYC failure. We
have observed clinical improvement with respiratory test
(table 1) without progression in lung CT changes.
Further studies would be necessary to establish this
therapeutic approach.
Published: 25 November 2010
doi:10.1186/1479-5876-8-S1-P45
Cite this article as: Muñoz et al.: Interstitial lung disease in patients with
scleroderma - Treatment with rituximab. Journal of Translational Medicine
2010 8(Suppl 1):P45.
Rheumatology, Valme University Hospital, Seville, Spain
Table 1
Pat.1. Pre-RTX Pat.1. Post-RTX Pat.2. Pre-RTX Pat.2. Post-RTX Pat. 3. Pre-RTX Pat.3. Post-RTX
Vital Cap (L) 1.94 (65.2%) 2.02 (68.5%) 1.08 (44.8%) 1.15 (48.3%) 1.43 (53.4%) 1.51 (56.7%)
FEV 1 1.75 (68.6%) 1.81 (71.6%) 1.08 (53.1%) 1.09 (54.5%) 1.12 (49.2%) 1.18 (52.2%)
FEV1/VC 90.35 89.69 99.91 94.86 78.38 78.15
TLCOc/VA (mol/min/Kpa) 1.20 (68%) 1.03 (59.2%) 0.93 (54.8%) 1.02 (60.6%) 1.20 (68.0%) 1.29 (73,8%)
PCO2 (mmHg) 44.1 42.8 32.6 40.2 33 35.1
PO2 (mmHg) 83 86 84 92 64 75
Sat O2 (%) 94.2 96.6 96.7 97.4 94.4 96.3
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